This week's Fierce Drug Delivery is brought to you by Catalent Biologics.
Wednesday, February 16 | 9am ET / 6am PT / 3pm CET
The biopharma industry continues to look for ways to improve patient compliance through the transition of intravenous (IV) to subcutaneous (SQ) administration and/or vial to pre-filled syringe (PFS) presentation. Both approaches are valuable alternatives for the increasing number of patients facing chronic illnesses such as rheumatoid arthritis and multiple sclerosis, and companies are also exploring these approaches for other indications, such as oncology. In this webinar, experts will discuss the formulation development challenges, considerations, and potential solutions associated with IV to SQ transitions, as well as vial to PFS, to ensure the product’s safety and efficacy.
|
| You are currently subscribed as newsletter@newslettercollector.com |
